WEST CHESTER, Pa., June 10, 2026--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted ...
MTTI is interested in funding the development of exploratory projects and larger initiatives that increase the overall research funding coming to MTTI members. It is not the place of MTTI to fund ...
The Michigan Tech Transportation Institute (MTTI) will provide the operating structure, resources, recognition, and leadership, in a collaborative environment, that supports research, education, and ...
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of ...
WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI), is delighted to be working with Brookline Capital Markets at the 2nd Targeted Radionuclide Pharmaceuticals (TRPs) ...
WEST CHESTER, Pa. & ISTANBUL — Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company ...
MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026 Molecular Targeting Technologies, ...
The Michigan Tech Transportation Institute (MTTI) provides the operating structure, resources, recognition, and leadership, in a collaborative environment, that supports research, education, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results